Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia

A systematic review and meta-analysis

Kentaro Matsui, Takahiro Tokumasu, Yoshiteru Takekita, Ken Inada, Tetsufumi Kanazawa, Taishiro Kishimoto, Shotaro Takasu, Hideaki Tani, Seiichiro Tarutani, Naoki Hashimoto, Hiroki Yamada, Yoshio Yamanouchi, Hiroyoshi Takeuchi

Research output: Contribution to journalArticle

Abstract

Background: While recent meta-analyses have reported the superiority of antipsychotic polypharmacy (APP) over antipsychotic monotherapy (APM) in schizophrenia, switching to APM can be beneficial in terms of side effects. To determine whether patients receiving APP should switch to APM or stay on APP, we conducted a systematic review and meta-analysis. Methods: Randomized controlled trials (RCTs) examining a switch from APP to APM vs. staying on APP were systematically selected from a previous meta-analysis comparing APP with APM in patients with schizophrenia. In addition, we conducted an updated systematic literature search using MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Data on study discontinuation, relapse, psychopathology, neurocognition, extrapyramidal symptoms, and body weight/body mass index (BMI) were extracted and synthesized. Results: A total of 6 RCTs involving 341 patients were included. All studies examined a switch from 2 antipsychotic agents to a single agent. Clozapine-treated patients were included in 3 studies. There was a significant difference in study discontinuation due to all causes in favor of staying on APP (N = 6, n = 341, RR = 2.28, 95% CI = 1.50–3.46, P < 0.001). There were no significant differences in relapse, any psychopathology, neurocognition, extrapyramidal symptoms, or body weight/BMI between the 2 groups. The quality of evidence was low to very low. Conclusions: The findings suggest that clinicians should closely monitor patient condition when switching to APM after receiving 2 antipsychotics. Given the low to very low overall quality of the evidence, the findings should be considered preliminary and inconclusive.

Original languageEnglish
JournalSchizophrenia Research
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Polypharmacy
Antipsychotic Agents
Meta-Analysis
Schizophrenia
Psychopathology
Body Mass Index
Randomized Controlled Trials
Body Weight
Recurrence
Clozapine

Keywords

  • Antipsychotics
  • Combination
  • Monotherapy
  • Polypharmacy
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia : A systematic review and meta-analysis. / Matsui, Kentaro; Tokumasu, Takahiro; Takekita, Yoshiteru; Inada, Ken; Kanazawa, Tetsufumi; Kishimoto, Taishiro; Takasu, Shotaro; Tani, Hideaki; Tarutani, Seiichiro; Hashimoto, Naoki; Yamada, Hiroki; Yamanouchi, Yoshio; Takeuchi, Hiroyoshi.

In: Schizophrenia Research, 01.01.2019.

Research output: Contribution to journalArticle

Matsui, Kentaro ; Tokumasu, Takahiro ; Takekita, Yoshiteru ; Inada, Ken ; Kanazawa, Tetsufumi ; Kishimoto, Taishiro ; Takasu, Shotaro ; Tani, Hideaki ; Tarutani, Seiichiro ; Hashimoto, Naoki ; Yamada, Hiroki ; Yamanouchi, Yoshio ; Takeuchi, Hiroyoshi. / Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia : A systematic review and meta-analysis. In: Schizophrenia Research. 2019.
@article{5d1391bb0f664d7cb80bc4800b945f4d,
title = "Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis",
abstract = "Background: While recent meta-analyses have reported the superiority of antipsychotic polypharmacy (APP) over antipsychotic monotherapy (APM) in schizophrenia, switching to APM can be beneficial in terms of side effects. To determine whether patients receiving APP should switch to APM or stay on APP, we conducted a systematic review and meta-analysis. Methods: Randomized controlled trials (RCTs) examining a switch from APP to APM vs. staying on APP were systematically selected from a previous meta-analysis comparing APP with APM in patients with schizophrenia. In addition, we conducted an updated systematic literature search using MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Data on study discontinuation, relapse, psychopathology, neurocognition, extrapyramidal symptoms, and body weight/body mass index (BMI) were extracted and synthesized. Results: A total of 6 RCTs involving 341 patients were included. All studies examined a switch from 2 antipsychotic agents to a single agent. Clozapine-treated patients were included in 3 studies. There was a significant difference in study discontinuation due to all causes in favor of staying on APP (N = 6, n = 341, RR = 2.28, 95{\%} CI = 1.50–3.46, P < 0.001). There were no significant differences in relapse, any psychopathology, neurocognition, extrapyramidal symptoms, or body weight/BMI between the 2 groups. The quality of evidence was low to very low. Conclusions: The findings suggest that clinicians should closely monitor patient condition when switching to APM after receiving 2 antipsychotics. Given the low to very low overall quality of the evidence, the findings should be considered preliminary and inconclusive.",
keywords = "Antipsychotics, Combination, Monotherapy, Polypharmacy, Schizophrenia",
author = "Kentaro Matsui and Takahiro Tokumasu and Yoshiteru Takekita and Ken Inada and Tetsufumi Kanazawa and Taishiro Kishimoto and Shotaro Takasu and Hideaki Tani and Seiichiro Tarutani and Naoki Hashimoto and Hiroki Yamada and Yoshio Yamanouchi and Hiroyoshi Takeuchi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.schres.2019.05.030",
language = "English",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

TY - JOUR

T1 - Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia

T2 - A systematic review and meta-analysis

AU - Matsui, Kentaro

AU - Tokumasu, Takahiro

AU - Takekita, Yoshiteru

AU - Inada, Ken

AU - Kanazawa, Tetsufumi

AU - Kishimoto, Taishiro

AU - Takasu, Shotaro

AU - Tani, Hideaki

AU - Tarutani, Seiichiro

AU - Hashimoto, Naoki

AU - Yamada, Hiroki

AU - Yamanouchi, Yoshio

AU - Takeuchi, Hiroyoshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: While recent meta-analyses have reported the superiority of antipsychotic polypharmacy (APP) over antipsychotic monotherapy (APM) in schizophrenia, switching to APM can be beneficial in terms of side effects. To determine whether patients receiving APP should switch to APM or stay on APP, we conducted a systematic review and meta-analysis. Methods: Randomized controlled trials (RCTs) examining a switch from APP to APM vs. staying on APP were systematically selected from a previous meta-analysis comparing APP with APM in patients with schizophrenia. In addition, we conducted an updated systematic literature search using MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Data on study discontinuation, relapse, psychopathology, neurocognition, extrapyramidal symptoms, and body weight/body mass index (BMI) were extracted and synthesized. Results: A total of 6 RCTs involving 341 patients were included. All studies examined a switch from 2 antipsychotic agents to a single agent. Clozapine-treated patients were included in 3 studies. There was a significant difference in study discontinuation due to all causes in favor of staying on APP (N = 6, n = 341, RR = 2.28, 95% CI = 1.50–3.46, P < 0.001). There were no significant differences in relapse, any psychopathology, neurocognition, extrapyramidal symptoms, or body weight/BMI between the 2 groups. The quality of evidence was low to very low. Conclusions: The findings suggest that clinicians should closely monitor patient condition when switching to APM after receiving 2 antipsychotics. Given the low to very low overall quality of the evidence, the findings should be considered preliminary and inconclusive.

AB - Background: While recent meta-analyses have reported the superiority of antipsychotic polypharmacy (APP) over antipsychotic monotherapy (APM) in schizophrenia, switching to APM can be beneficial in terms of side effects. To determine whether patients receiving APP should switch to APM or stay on APP, we conducted a systematic review and meta-analysis. Methods: Randomized controlled trials (RCTs) examining a switch from APP to APM vs. staying on APP were systematically selected from a previous meta-analysis comparing APP with APM in patients with schizophrenia. In addition, we conducted an updated systematic literature search using MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Data on study discontinuation, relapse, psychopathology, neurocognition, extrapyramidal symptoms, and body weight/body mass index (BMI) were extracted and synthesized. Results: A total of 6 RCTs involving 341 patients were included. All studies examined a switch from 2 antipsychotic agents to a single agent. Clozapine-treated patients were included in 3 studies. There was a significant difference in study discontinuation due to all causes in favor of staying on APP (N = 6, n = 341, RR = 2.28, 95% CI = 1.50–3.46, P < 0.001). There were no significant differences in relapse, any psychopathology, neurocognition, extrapyramidal symptoms, or body weight/BMI between the 2 groups. The quality of evidence was low to very low. Conclusions: The findings suggest that clinicians should closely monitor patient condition when switching to APM after receiving 2 antipsychotics. Given the low to very low overall quality of the evidence, the findings should be considered preliminary and inconclusive.

KW - Antipsychotics

KW - Combination

KW - Monotherapy

KW - Polypharmacy

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85066821569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066821569&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2019.05.030

DO - 10.1016/j.schres.2019.05.030

M3 - Article

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -